P-733 A non-selection study to evaluate non-invasive preimplantation genetic testing for aneuploidy

Abstract Study question How does non-invasive preimplantation genetic testing for aneuploidy (niPGT-A) perform to predict sustained implantation or live birth (SI/LB)? Summary answer Though not comparable conventional PGT-A, niPGT-A can still be considered an appealing tool clinical embryo prioritizing given its high negative predictive value (NPV). What is known already To omit the need invasive trophectoderm biopsy, which screens embryonic ploidy using cell free DNA released into spent culture medium (SEM) blastocoel fluid (BF) was developed. Although feasibility of has been shown and healthy births have reported from embryos screened by niPGT-A, transfer outcome established yet evidence lacking as whether selection associated with improved pregnancy outcomes. The answers these are vital importance justify care. design, size, duration This a single center, blinded, non-selection study consisting frozen cycles two years, 117 (Arm-1) were completed 83 patients transferring that only morphologically assessed, 90 (Arm-2) 67 euploid biopsy-based PGT-A. Participants/materials, setting, methods Embryos cultured in 25 μL continuous until blastocyst stage. “SEM+BF” samples ongoingly collected archived at end culture. In Arm-1, after outcomes determined, corresponding pulled out niPGT-A. Arm-2, also performed some cases did up SI/LB. NiPGT-A NICS incorporated ChromGo platform (Yikon Genomics). Main results role chance Out 110 (94%) yielded informative result. Among these, 46 transferred determined “euploid” 15 resulted SI/LB; 32 “aneuploid” 27 Therefore, positive values (PPV NPV) 32.6% (15/46) 84.4% (27/32), respectively. Another Arm-1 “suspected mosaic” they showed similar rate SI/LB per those ones (37.5% vs. 32.6%, P = 0. 8092). Compared overall, “transferrable” (“euploid” + mosaic”) much higher (34.6% 27.6%, 0.3399). 39 “Euploid” PGT-A significantly better than (43.3% 0.0243). 51 SI/LB, tested 6 being 3 “abnormal/aneuploid”, raising concern possible false Limitations, reasons caution enrolled non-selected patient population inclusion few history repeated failure. PPV might underestimated failure could attributed defects endometrial receptivity rather quality. Wider implications findings first validate setting medium. indicates clinics system. It forms foundation prospective, randomized controlled trial further assess benefit Trial registration number Not applicable